Company: CSTL
Filing Date: 2025-03-28
Form Type: PRE 14A
Source: 0001447362-25-000050
Chunk: 49

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-03-28
Form: PRE 14A
Chunk 49
---
holder feedback we received and peer-group benchmarks, in 2022 we introduced PSUs that vest upon the achievement of specified performance criteria and a specific service period into the long-term incentive component of our executive compensation program. In 2023, we shifted the timing of the grant of equity awards to our executive officers from the fourth quarter of our fiscal year to the first quarter of our subsequent fiscal year so that we had the benefit of our final, Board-approved budget and our financial results, prior to setting performance goals for the executive officers’ PSUs and to align total equity awards with performance. In 2024, to mitigate overlapping metrics between short-term and long-term incentives, the 2024 PSU performance period was increased from two years to three years and in addition to revenue, the metrics also included the commercial launch of certain pipeline test and achieving positive EBITDA by end of 2026.

#### 48Castle Biosciences 2025 Proxy Statement

#### Compensation Discussion and Analysis
Our executive compensation program is designed to link a significant portion of the compensation of our executive officers to defined performance standards that we believe properly incentive our executive officers to strive for near-term earnings and returns as well as growth in long-term stockholder value.

#### 2024 STOCKHOLDER OUTREACH
For many years, we followed a consistent approach to the design of our executive compensation program. At our 2024 annual meeting of stockholders, we asked our stockholders to indicate their support for the compensation of our named executive officers by casting a non-binding, advisory vote “FOR” such compensation as described in the proxy statement Say-on-Pay proposal. Our Say-on-Pay proposal received the support of approximately 97% of the votes cast. The Board is appreciative of this support and believes it indicates that stockholders are supportive of our pay program structure and the alignment we have created between management and stockholder interests. A key focus of our ongoing engagement with stockholders in 2024 was to continue the communication with respect to our executive compensation programs. We continued to conduct a robust, Board-driven stockholder outreach and engagement program in the fall of 2024, which informed the Board’s decisions for 2025. We strive to continuously improve our compensation program to drive strong alignment with Company performance and with our stockholders’ expectations.

We continued to engage Morrow Sodali LLC in 2024 to assist our Board with certain governance matters and to facilitate a direct stockholder outreach program. We initiated our 2024 stockholder outreach in the fourth quarter to